Buprenorphine for the treatment of perinatal opioid dependence: pharmacology and implications for antepartum, intrapartum, and postpartum care
Pharmacy, Obstetrics & Gynecology
Journal of midwifery & women's health
Buprenorphine (pharmacology); Female; Humans; Narcotic Antagonists (pharmacology); Off-Label Use; Opioid-Related Disorders (complications, drug therapy); Perinatal Care; Postpartum Period; Pregnancy; Pregnancy Complications (drug therapy)
Opioid dependence during pregnancy is associated with significant health risks for both the mother and her fetus. Opioid maintenance therapy with methadone (Dolophine) is the current standard of care, reduces medical and social risks associated with illicit drug use, and decreases rates of prematurity and low birth weight. However, treatment with methadone is frequently associated with neonatal abstinence syndrome. Buprenorphine is an alternative to methadone that preliminary data indicates is equivalent in safety and efficacy to methadone and significantly increases access to treatment. The pharmacology of buprenorphine and its implications for the care of pregnant women with opioid dependence are described.
Goodman D. Buprenorphine for the treatment of perinatal opioid dependence: pharmacology and implications for antepartum, intrapartum, and postpartum care. J Midwifery Womens Health. 2011;56(3):240-247. doi:10.1111/j.1542-2011.2011.00049.x